Guidance for Ultragenyx Pharmaceutical Inc. (RARE)
| Period | Range | Estimate | Revenue Range | Revenue Estimate | Target | Details |
|---|---|---|---|---|---|---|
| 2026 | N/A | N/A | $730.00M – 760.00M | $746.20M | = Maintained | Details |
| 2026 | N/A | N/A | $730.00M – 760.00M | $790.70M | = Maintained | Details |
| 2025 | N/A | N/A | $640.00M – 670.00M | $657.40M | = Maintained | Details |
| 2025 | N/A | N/A | $640.00M – 670.00M | $655.80M | = Maintained | Details |
| 2025 | N/A | N/A | $640.00M – 670.00M | $651.90M | = Maintained | Details |
| 2024 | N/A | N/A | $530.00M – 550.00M | $537.00M | = Maintained | Details |
| 2024 | N/A | N/A | $530.00M – 550.00M | $512.00M | = Maintained | Details |
| 2021 | N/A | N/A | $180.00M – 190.00M | N/A | = Maintained | Details |
| 2020 | N/A | N/A | $125.00M – 140.00M | $176.86M | = Maintained | Details |
| Q3 2018 | N/A | N/A | N/A | N/A | = Maintained | Details |
| Q2 2018 | N/A | N/A | N/A | N/A | = Maintained | Details |
| Q1 2018 | N/A | N/A | N/A | N/A | = Maintained | Details |
| Q4 2017 | N/A | N/A | N/A | N/A | = Maintained | Details |
| Q3 2017 | N/A | N/A | N/A | N/A | = Maintained | Details |
| Q2 2017 | N/A | N/A | N/A | N/A | = Maintained | Details |
| Q1 2017 | N/A | N/A | N/A | N/A | = Maintained | Details |
